ClinicalTrials.gg
TerminatedNCT03119701INFORAAAUpdated Jan 14, 2021Results posted

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

A Phase 2 interventional study of Interferon Beta-1A and Placebo in Preventive Medicine and Multi Organ Failure, sponsored by Faron Pharmaceuticals Ltd. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.

Sponsored by Faron Pharmaceuticals Ltd · Phase 2, Interventional, and Prevention

Why this study was terminated
IDMC recommendation. Unexpectedly high use of concomitant corticosteroid treatment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm

Read the detailed description

This trial is multicentre, randomised, double-blinded, Phase II, parallel group comparison study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm. Investigational medicinal product will be administered as post-surgical preventive treatment either 10µg FP-1201-lyo or placebo. Treatment will be administered daily every 24 hrs for 6 days. The first dose will be given after successful surgery at the point when the patient arrives to the Intensive Care Unit (ICU).

Both treatment groups will receive standard supportive care.

Aim is randomise and initiate treatment of 152 patients. For the final analysis, a minimum of 129 evaluable patients will be required.

02

Conditions studied

  • Preventive Medicine
  • Multi Organ Failure

Keywords

  • Patients Surviving Open Surgery
  • Ruptured Abdominal Aortic Aneurysm
03

In context

Multiple Organ Failure

193 studies on the registry are indexed under Multiple Organ Failure; 47 are open to participants now.

This study's enrollment of 40 is below the median of 88 across 90 interventional studies indexed under Multiple Organ Failure.

Browse Multiple Organ Failure studies →

Lead sponsor

Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria during screening and prior to the first dose of study medication being administered on D0 (criteria 1 or 2 and all 3, 4 and 5):

  1. Patients (male or female) presenting with a ruptured abdominal aortic aneurysm (RAAA) diagnosed by ultrasound or CT-scan in the emergency room

    • all forms of infrarenal RAAAs with or without coexisting iliac aneurysms are included or
  2. Patients (male or female) presenting with symptoms of RAAA known to have an infrarenal AAA and proceeding straight to open repair without radiological assessment and confirmed rupture (=retroperitoneal haematoma) in operation

    and

  3. Aneurysma repair must be infra-renal, i.e. the proximal anastomosis must be below the renal arteries and the renal arteries have to stay intact. Temporary above the renal clamping can be used for a maximum of 30 minutes (total clamping time)

    and

  4. Patients providing

    and

  5. Age of 18 years or higher

Exclusion criteria

Exclusion Criteria:

To be eligible for inclusion into this study, each patient must not meet any of the following exclusion criteria during screening or prior to the first dose of study medication being administered:

  1. Moribund patient not eligible for treatment in ICU or expected to survive surgery
  2. Markedly short , e.g. advanced malignant disease
  3. Current participation in another experimental treatment protocol
  4. Significant congestive heart failure, defined as (NYHA) class IV
  5. Current treatment with Interferon (IFN) alpha or IFN beta
  6. Dialysis therapy for chronic renal failure
  7. Irreversible shock from haemorrhage
  8. Unconsciousness or inability to give consent
  9. Ruptured Endovascular Aortic Repair (rEVAR) first (prior attempt for endovascular aortic repair for the current rupture)
  10. Diagnosed cirrhosis
  11. Pregnancy and women with child bearing potential without negative pregnancy test
  12. Rupture not confirmed by CT or intra-operatively (impending ruptures are excluded)
  13. RAAA requiring repair of the renal arteries or the proximal aorta

    • thoracoabdominal aneurysms requiring immediate repair
    • damaged renal arteries during emergency clamping requiring repair

Note:

  • temporary clamping above the renal arteries (max 30 min total clamping time above the renal arteries) does not lead to exclusion
  • ligation of the left renal vein does not lead to exclusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    FP-1201-lyo 10 µg

    FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days. Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.

    Drug: Interferon Beta-1A

  • Placebo comparator
    FP-1201-lyo Placebo

    FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days. Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection

    Drug: Placebo

Interventions

  • Lyophilisate for solution for injection.

    Also known as: FP-1201-lyo, ATC code L03AB07

  • DrugPlacebo

    Lyophilisate for solution for injection as placebo.

    Also known as: Placebo for investigational drug

06

What researchers measure

Primary outcomes

  1. The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality

    Number of fatalities

    Time frame: Day 30

Secondary outcomes

  1. The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality

    Number of fatalities

    Time frame: Day 90

  2. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs)

    Number of ventilator free days. VFDs to Day 30 were defined as the number of calendar days after initiating unassisted breathing (UAB) to Day 30 from first treatment, assuming that a patient survives at least 48 consecutive hours after initiating UAB. Patients who die without initiating UAB were assigned a VFD value of zero.

    Time frame: Day 30

  3. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Days Receiving Hemodialysis

    Number of days receiving hemodialysis. There were only few reported values other than zero.

    Time frame: Day 30 and Day 90

  4. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score

    Organ failure free days were defined as the number of days in the first 30 days after the first dose of study medication that the patient was alive and free of organ failure with a SOFA score of zero for the following six organ parameters: respiration, coagulation, liver, cardiovascular, central nervous system and renal function. It is graded from 0 to 4 according to the degree of dysfunction/ failure (higher scores indicate more severe organ failure). Patients who died without achieving a SOFA score of zero was assigned an organ failure free days value of zero. Note: the information for organ failure free days has been only collected when the patients have been in the Intensive Care Unit (ICU). As ICU free days have been reported in a separate variable, it was decided that presented information will be kept, without trying to conduct imputation.

    Time frame: Day 30

  5. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Prevalence of Abdominal Compartment Syndrome by Intra-abdominal Pressure (IAP)

    Intra-abdominal pressure values, which were routinely measured during ICU stay via urine bladder catheter.

    Time frame: Days 1 - 6, D9 and D13 during Intensive Care Unit (ICU) stay

  6. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Neutralizing Antibodies Against IFN Beta-1a (NAbs) in Whole Blood Samples

    IFN beta-1a neutralizing antibodies immune response. Blood samples for the NAbs assessments were collected at Day 0 pre-dose (baseline) and at Day 30.

    Time frame: Day 30

  7. The Efficacy of FP-1201-lyo Compared to Placebo Concerning Disability by Modified Ranking Scale (mRS).

    Scale gives the degree of disability or dependence in the daily activities. Single mRS value is applied for every patient based on patient or caregiver interview. The scale runs from 0-6, from perfect health without symptoms to death. Pre-operation Baseline Visit mRS value is collected for reference.

    Time frame: Day 90

  8. Safety Parameters of Clinically Significant Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events, Vital Signs and Clinical Laboratory Parameters

    Number of TEAEs from vital signs data, laboratory data, physical examinations and spontaneous reporting when conscious.

    Time frame: Day 0 to Day 30

  9. Pharmacoeconomic Information of Length of ICU Stay, Length of Hospital Stay, Length of Stay at Another Health Care Facility, Length of Hemodialysis Needed, Ventilation Free Days

    Economic measurement: * Length of ICU stay, in terms of ICU free days at D30 * Length of hospital stay, in terms of hospital free days at D90 * Length of stay at another health care facility at D90 * The number of days on hemodialysis at D30 and at D90 * The number of organ failure free days at D30 * The number of ventilation free days at D30

    Time frame: Day 30 or Day 90

Other outcomes

  1. Myxovirus Resistant Protein A (MxA) Concentration in Whole Blood Samples as Pharmacodynamic Marker

    Concentration of Myxovirus Resistant Protein A (MxA)

    Time frame: Day 0 up to Day 13

  2. Tentative Disease Specific Marker Cluster of Differentiation 73 (CD73, Ecto-5'-Nucleotidase Enzyme) Concentration in Serum Samples

    CD73 (ecto-5'-nucleotidase enzyme) concentration

    Time frame: Day 0 up to Day 13

  3. Tentative Disease Specific, Potential Inflammatory Marker - Interleukin 6 (IL-6) in Serum Samples

    IL-6 concentration.

    Time frame: Day 0 up to Day 13

  4. Tentative Disease Specific, Potential Inflammatory Marker - Hepatocyte Growth Factor [HGF]) in Serum Samples

    HGF concentration.

    Time frame: Day 0 up to Day 13

07

Results

Posted Jan 14, 2021
Limitations and caveats
The study was prematurely stopped and due to this the planned statistical power for the primary comparisons was not reached.

Participant flow

6-day Dosing
Participant flow — 6-day Dosing
MilestoneFP-1201-lyo 10 µgFP-1201-lyo Placebo
Started2911
Completed228
Not completed73
Withdrew: Death41
Withdrew: Adverse event30
Withdrew: Physician decision01
Withdrew: Withdrawal by subject01
Mid-term (Final) Follow-up at D90
Participant flow — Mid-term (Final) Follow-up at D90
MilestoneFP-1201-lyo 10 µgFP-1201-lyo Placebo
Started2510
Completed229
Not completed31
Withdrew: Death31

Outcome measures

PrimaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality

Number of fatalities

Time frame:
Day 30
Reported as:
Count of participants · Participants
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality
ParticipantsFP-1201-lyo 10 µgFP-1201-lyo Placebo
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality62
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · Regression, Logistic · p = 0.78 (The threshold for statistical significance was p = 0.05.) · Odds ratio (or): 1.30 · 95% CI 0.21 to 8.19
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality

Number of fatalities

Time frame:
Day 90
Reported as:
Count of participants · Participants
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality
ParticipantsFP-1201-lyo 10 µgFP-1201-lyo Placebo
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality72
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · Regression, Logistic · p = 0.57 (The threshold for statistical significance was p = 0.05.) · Odds ratio (or): 1.7 · 95% CI 0.28 to 10.52
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs)

Number of ventilator free days. VFDs to Day 30 were defined as the number of calendar days after initiating unassisted breathing (UAB) to Day 30 from first treatment, assuming that a patient survives at least 48 consecutive hours after initiating UAB. Patients who die without initiating UAB were assigned a VFD value of zero.

Time frame:
Day 30
Reported as:
Median · days
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs)
daysFP-1201-lyo 10 µgFP-1201-lyo Placebo
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs)25.0 (0.0 to 30.0)29.0 (0.0 to 29.0)
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · Wilcoxon (Mann-Whitney) · p = 0.08 (The threshold for statistical significance was p = 0.05.)
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Days Receiving Hemodialysis

Number of days receiving hemodialysis. There were only few reported values other than zero.

Time frame:
Day 30 and Day 90
Reported as:
Mean · days
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Days Receiving Hemodialysis
daysFP-1201-lyo 10 µgFP-1201-lyo Placebo
Day 300.9 ± 4.150.0 ± 0.00
Day 900.6 ± 2.680.0 ± 0.00
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score

Organ failure free days were defined as the number of days in the first 30 days after the first dose of study medication that the patient was alive and free of organ failure with a SOFA score of zero for the following six organ parameters: respiration, coagulation, liver, cardiovascular, central nervous system and renal function. It is graded from 0 to 4 according to the degree of dysfunction/ failure (higher scores indicate more severe organ failure). Patients who died without achieving a SOFA score of zero was assigned an organ failure free days value of zero. Note: the information for organ failure free days has been only collected when the patients have been in the Intensive Care Unit (ICU). As ICU free days have been reported in a separate variable, it was decided that presented information will be kept, without trying to conduct imputation.

Time frame:
Day 30
Reported as:
Mean · days
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score
daysFP-1201-lyo 10 µgFP-1201-lyo Placebo
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score0.0 ± 0.000.0 ± 0.00
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · Wilcoxon (Mann-Whitney) · p = >0.999 (The threshold for statistical significance was p = 0.05.)
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Prevalence of Abdominal Compartment Syndrome by Intra-abdominal Pressure (IAP)

Intra-abdominal pressure values, which were routinely measured during ICU stay via urine bladder catheter.

Time frame:
Days 1 - 6, D9 and D13 during Intensive Care Unit (ICU) stay
Reported as:
Mean · mmHg
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Prevalence of Abdominal Compartment Syndrome by Intra-abdominal Pressure (IAP)
mmHgFP-1201-lyo 10 µgFP-1201-lyo Placebo
Day 115.4 ± 12.3710.3 ± 4.80
Day 212.2 ± 3.5812.1 ± 6.01
Day 313.1 ± 4.6210.3 ± 5.35
Day 411.4 ± 6.608.6 ± 5.32
Day 510.5 ± 3.1412.5 ± 5.45
Day 611.4 ± 5.2915.0 ± 0
Day 911.0 ± 5.48—
Day 1310.8 ± 4.49—
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Neutralizing Antibodies Against IFN Beta-1a (NAbs) in Whole Blood Samples

IFN beta-1a neutralizing antibodies immune response. Blood samples for the NAbs assessments were collected at Day 0 pre-dose (baseline) and at Day 30.

Time frame:
Day 30
Reported as:
Count of participants · Participants
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Neutralizing Antibodies Against IFN Beta-1a (NAbs) in Whole Blood Samples
ParticipantsFP-1201-lyo 10 µgFP-1201-lyo Placebo
Baseline00
Day 3000
SecondaryThe Efficacy of FP-1201-lyo Compared to Placebo Concerning Disability by Modified Ranking Scale (mRS).

Scale gives the degree of disability or dependence in the daily activities. Single mRS value is applied for every patient based on patient or caregiver interview. The scale runs from 0-6, from perfect health without symptoms to death. Pre-operation Baseline Visit mRS value is collected for reference.

Time frame:
Day 90
Reported as:
Count of participants · Participants
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Disability by Modified Ranking Scale (mRS).
ParticipantsFP-1201-lyo 10 µgFP-1201-lyo Placebo
No symptoms - 052
No significant disability - 155
Slight disability - 231
Moderate disability - 320
Moderately severe disability - 430
Severe disability - 521
Death - 672
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · Mantel Haenszel · p = 0.3620 (The threshold for statistical significance was p = 0.05.)Exact Mantel-Haenszel Chi-Square Test
SecondarySafety Parameters of Clinically Significant Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events, Vital Signs and Clinical Laboratory Parameters

Number of TEAEs from vital signs data, laboratory data, physical examinations and spontaneous reporting when conscious.

Time frame:
Day 0 to Day 30
Reported as:
Number · Events
Safety Parameters of Clinically Significant Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events, Vital Signs and Clinical Laboratory Parameters
EventsFP-1201-lyo 10 µgFP-1201-lyo Placebo
Product-related TEAEs171
Severe TEAEs282
Serious TEAEs265
TEAEs Leading to Study Product Discontinuation71
TEAEs Leading to Death71
SecondaryPharmacoeconomic Information of Length of ICU Stay, Length of Hospital Stay, Length of Stay at Another Health Care Facility, Length of Hemodialysis Needed, Ventilation Free Days

Economic measurement: * Length of ICU stay, in terms of ICU free days at D30 * Length of hospital stay, in terms of hospital free days at D90 * Length of stay at another health care facility at D90 * The number of days on hemodialysis at D30 and at D90 * The number of organ failure free days at D30 * The number of ventilation free days at D30

Time frame:
Day 30 or Day 90
Reported as:
Mean · days
Pharmacoeconomic Information of Length of ICU Stay, Length of Hospital Stay, Length of Stay at Another Health Care Facility, Length of Hemodialysis Needed, Ventilation Free Days
daysFP-1201-lyo 10 µgFP-1201-lyo Placebo
ICU free days at Day 3016.8 ± 12.3921.9 ± 11.06
Days in hospital at Day 9018.1 ± 9.8413.8 ± 9.97
Days in another facility at Day 9011.8 ± 23.797.0 ± 19.80
Days on hemodialysis at Day 300.9 ± 4.150.0 ± 0.00
Days on hemodialysis at Day 900.6 ± 2.680.0 ± 0.00
Organ failure free days at Day 300.0 ± 0.000.0 ± 0.00
Ventilation free days at Day 3020.6 ± 10.6225.1 ± 8.85
Other pre-specifiedMyxovirus Resistant Protein A (MxA) Concentration in Whole Blood Samples as Pharmacodynamic Marker

Concentration of Myxovirus Resistant Protein A (MxA)

Time frame:
Day 0 up to Day 13
Reported as:
Geometric mean · ng/mL
Myxovirus Resistant Protein A (MxA) Concentration in Whole Blood Samples as Pharmacodynamic Marker
ng/mLFP-1201-lyo 10 µgFP-1201-lyo Placebo
Baseline3.5 (2.4 to 5.1)6.0 (3.3 to 11.0)
Day 115.0 (10.2 to 22.1)5.1 (2.8 to 9.3)
Day 219.8 (13.5 to 29.1)3.8 (2.1 to 7.0)
Day 321.2 (14.3 to 31.4)3.3 (1.8 to 6.2)
Day 436.4 (24.4 to 54.2)4.1 (2.2 to 7.7)
Day 548.3 (32.3 to 72.3)3.1 (1.6 to 5.8)
Day 650.4 (33.9 to 75.1)3.6 (1.9 to 6.8)
Day 914.3 (9.5 to 21.5)4.8 (2.4 to 9.7)
Day 133.9 (2.5 to 5.9)8.7 (3.7 to 20.7)
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = <.0001 (Day 2, Day 3, Day 4, Day 5, and Day 6.)Repeated measures ANOVA
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.13 (Baseline visit)Repeated measures ANOVA
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.0035 (Day 1)Repeated measures ANOVA
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.009 (Day 9)Repeated measures ANOVA
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.10 (Day 13)Repeated measures ANOVA
Other pre-specifiedTentative Disease Specific Marker Cluster of Differentiation 73 (CD73, Ecto-5'-Nucleotidase Enzyme) Concentration in Serum Samples

CD73 (ecto-5'-nucleotidase enzyme) concentration

Time frame:
Day 0 up to Day 13
Reported as:
Geometric mean · ng/mL
Tentative Disease Specific Marker Cluster of Differentiation 73 (CD73, Ecto-5'-Nucleotidase Enzyme) Concentration in Serum Samples
ng/mLFP-1201-lyo 10 µgFP-1201-lyo Placebo
Baseline2.1 (1.8 to 2.5)2.2 (1.7 to 2.9)
Day 12.0 (1.7 to 2.4)2.2 (1.6 to 2.8)
Day 22.2 (1.8 to 2.6)2.2 (1.7 to 3.0)
Day 32.0 (1.7 to 2.4)2.3 (1.7 to 3.1)
Day 42.3 (1.9 to 2.8)2.6 (1.9 to 3.5)
Day 53.0 (2.4 to 3.6)3.5 (2.6 to 4.8)
Day 63.8 (3.2 to 4.6)3.8 (2.7 to 5.2)
Day 93.9 (3.2 to 4.8)3.8 (2.6 to 5.4)
Day 132.9 (2.3 to 3.6)2.7 (1.7 to 4.3)
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.66 (The threshold for statistical significance was p = 0.05.)Repeated measures ANOVA
Other pre-specifiedTentative Disease Specific, Potential Inflammatory Marker - Interleukin 6 (IL-6) in Serum Samples

IL-6 concentration.

Time frame:
Day 0 up to Day 13
Reported as:
Geometric mean · pg/mL
Tentative Disease Specific, Potential Inflammatory Marker - Interleukin 6 (IL-6) in Serum Samples
pg/mLFP-1201-lyo 10 µgFP-1201-lyo Placebo
Baseline328.9 (223.8 to 483.3)378.9 (207.3 to 692.6)
Day 1493.1 (335.5 to 724.5)460.2 (251.8 to 841.0)
Day 3181.4 (122.0 to 270.0)130.7 (69.8 to 244.8)
Day 6164.1 (108.1 to 249.2)79.1 (39.8 to 157.1)
Day 9107.9 (69.9 to 166.5)74.5 (34.4 to 161.5)
Statistical analysis
  • FP-1201-lyo 10 µg vs FP-1201-lyo Placebo · ANOVA · p = 0.3 (The threshold for statistical significance was p = 0.05.)Repeated measures ANOVA
Other pre-specifiedTentative Disease Specific, Potential Inflammatory Marker - Hepatocyte Growth Factor [HGF]) in Serum Samples

HGF concentration.

Time frame:
Day 0 up to Day 13

No measurements were reported for this outcome.

Adverse events

Collected over The Adverse Event (AE) reporting period was up to study D30. In accordance with the protocol, the investigators reported AEs occurring after D30 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until D90.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP-1201-lyo 10 µg7/29 (24.1%)13/29 (44.8%)27/29 (93.1%)
FP-1201-lyo Placebo2/11 (18.2%)3/11 (27.3%)9/11 (81.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventFP-1201-lyo 10 µgFP-1201-lyo Placebo
Multiple organ dysfunction syndromeGeneral disorders4/290/11
Intestinal ischaemiaGastrointestinal disorders3/291/11
Large intestine perforationGastrointestinal disorders3/290/11
PneumoniaInfections and infestations0/291/11
Pulmonary contusionInjury, poisoning and procedural complications0/291/11
Road traffic accidentInjury, poisoning and procedural complications0/291/11
Sternal fractureInjury, poisoning and procedural complications0/291/11
Gastrointestinal necrosisGastrointestinal disorders2/290/11
Myocardial ischaemiaCardiac disorders1/290/11
Gastric ulcer haemorrhageGastrointestinal disorders1/290/11
Most frequent other events
Showing 10 of 87
Most frequent other events
EventFP-1201-lyo 10 µgFP-1201-lyo Placebo
Atrial fibrillationCardiac disorders5/293/11
PyrexiaGeneral disorders6/291/11
Confusional statePsychiatric disorders4/292/11
HypertensionVascular disorders4/292/11
Haemoglobin decreasedInvestigations4/291/11
ConstipationGastrointestinal disorders3/290/11
C-reactive protein increasedInvestigations3/291/11
Hepatic enzyme increasedInvestigations3/290/11
HypokalaemiaMetabolism and nutrition disorders3/291/11
Haemorrhagic anaemiaBlood and lymphatic system disorders0/291/11

Baseline characteristics

A total of 40 subjects received at least 1 dose of study drug. 2 patients were excluded from Full Analysis Set for Efficacy (FAS-E) and Per Protocol Set (PPS) populations due to early deaths (within 36 hours from first dose of the study treatment). Therefore, FAS-E and PPS populations consisted of 38 patients.

Age, Customized
Age, Customized(Participants)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
< 70 years7310
70-80 years14620
> 80 years628
Sex: Female, Male
Sex: Female, Male(Participants)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
Female404
Male231134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White271138
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
Finland23831
Lithuania314
Estonia123
Baseline Height
Baseline Height(centimetres)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
Mean172.3 ± 6.34177.5 ± 7.59173.8 ± 7.05
Baseline Weight
Baseline Weight(kilograms)FP-1201-lyo 10 µgFP-1201-lyo PlaceboTotal
Mean82.0 ± 16.1495.9 ± 21.2186.0 ± 18.58
08

Study locations

9 sites
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • Helsinki University Hospital
    Helsinki, FI-00290, Finland
  • Central Finland Central Hospital
    Jyväskylä, FI-40620, Finland
  • South Karelia Central Hospital
    Lappeenranta, FI-53130, Finland
  • Oulu University Hospital
    Oulu, FI-90220, Finland
  • Tampere University Hospital
    Tampere, FI-33520, Finland
  • Turku University Hospital
    Turku, FFI-20520, Finland
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, LT-50161, Lithuania
  • Vilnius University Hospital Santaros klinikos
    Vilnius, LT-08661, Lithuania
09

References and documents

Publications

  • Hakovirta H, Jalkanen J, Saimanen E, Kukkonen T, Romsi P, Suominen V, Vikatmaa L, Valtonen M, Karvonen MK, Venermo M; INFORAAA Study Group. Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled study. Sci Rep. 2022 Feb 3;12(1):1839. doi: 10.1038/s41598-022-05771-1. PubMed 35115574 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Sep 2019, 31 months.

Results were first posted in Jan 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2017
First posted
Apr 19, 2017
StartActual
Feb 18, 2017
Primary completionActual
Sep 23, 2019
CompletionActual
Oct 3, 2019
Results first posted
Jan 14, 2021
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03119701
Lead sponsor
Faron Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Apr 19, 2017
Start date
Feb 18, 2017
Primary completion
Sep 23, 2019
Completion
Oct 3, 2019
Results posted
Jan 14, 2021
Last update
Jan 14, 2021

Study contacts

Harri Hakovirta, MD
principal investigator · Turku University Hospital
Maarit Venermo, MD
principal investigator · Helsinki University Central Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion